Lung IL-13 gene signatures are associated with raised tissue eosinophils in COPD
Eosinophilic lung inflammation is related to exacerbation frequency, but lung eosinophils are not predicted by blood eosinophil counts in COPD. Our data suggest IL-13-mediated pathways may be responsible for the presence of tissue eosinophils in COPD. Further work to establish more predictive biomarkers of lung eosinophil biology are required to unlock this axis to optimised treatment.
Authors
- Maria G. Belvisi (ORCID: https://orcid.org/0000-0003-1652-4370)
- Karl J. Staples (ORCID: https://orcid.org/0000-0003-3844-6457)
- C. Mirella Spalluto (ORCID: https://orcid.org/0000-0001-7273-0844)
- Ventzislava A. Hristova (ORCID: https://orcid.org/0000-0003-0427-5696)
- Jodie Ackland (ORCID: https://orcid.org/0000-0003-3120-3620)
- Kristoffer Ostridge (ORCID: https://orcid.org/0000-0001-8910-3900)
- Lisa Öberg (ORCID: https://orcid.org/0000-0001-7127-1711)
- Michael Hühn
- Ashley Heinson (ORCID: https://orcid.org/0000-0001-8695-6203)
- Daniel Muthas (ORCID: https://orcid.org/0000-0001-9320-2004)
- Graham Belfield
- Raghothama Chaerkady
- Damla Etal
- Adam Platt (ORCID: https://orcid.org/0009-0008-0109-7699)
- Christopher McCrae (ORCID: https://orcid.org/0000-0001-7184-9069)
- Tom Wilkinson (ORCID: https://orcid.org/0000-0003-1771-3851)
- Sonja Y. Hess (ORCID: https://orcid.org/0000-0002-5904-9816)
- B. Angermann (ORCID: https://orcid.org/0000-0002-1328-8790)
- Alastair Watson (ORCID: https://orcid.org/0000-0002-6735-2567)
- Sruthymol Lukose
Institutions
- AstraZeneca (United Kingdom) (GB)
- University Hospital Southampton NHS Foundation Trust (GB)
- NIHR Southampton Biomedical Research Centre (GB)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (United States) (US)
- University of Southampton (GB)
- Imperial College London (GB)
Publication Details
- Journal
- Respiratory Research
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1186/s12931-025-03177-x
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- AstraZeneca
- National Institute for Health and Care Research
- AAIR Charity
- National Institute for Health Research Southampton Biomedical Research Centre